AnaptysBio CEO Sells Over $1 Million in Shares

Daniel Faga's stock sale represents a 3.44% decrease in his position

Mar. 28, 2026 at 8:07am

Got story updates? Submit your updates here. ›

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 17,679 shares of the company's stock in a transaction on Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the transaction, Faga now owns 495,965 shares in the company, valued at $30,556,403.65.

Why it matters

Insider stock sales can provide insight into a company's performance and leadership's confidence in the business. This transaction represents a 3.44% decrease in Faga's position, which may signal a shift in his outlook on AnaptysBio's prospects.

The details

The stock sale was disclosed in a legal filing with the Securities & Exchange Commission. Faga has made several other stock sales in recent months, including transactions in January that totaled over $1.7 million.

  • The stock sale occurred on Friday, March 27th, 2026.
  • Faga also made stock sales in January 2026 totaling over $1.7 million.

The players

Daniel Faga

The CEO of AnaptysBio, Inc. (NASDAQ:ANAB).

AnaptysBio, Inc.

A clinical-stage biotechnology company focused on developing therapeutic antibody products for immunology and inflammation.

Got photos? Submit your photos here. ›

What they’re saying

“This trade represents a 3.44% decrease in their position.”

— Daniel Faga, CEO

What’s next

Investors will likely continue to monitor AnaptysBio's stock performance and any further insider trading activity by CEO Daniel Faga.

The takeaway

Insider stock sales can provide clues about a company's outlook, though the reasons behind the transactions are not always clear. Shareholders will be watching to see if Faga's sale signals broader concerns or is simply part of his personal financial planning.